Parkinson's DiseaseNCT07569133
Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease
A study testing Repetitive Transcranial Magnetic Stimulation (rTMS) in people with Parkinson's Disease and Depression, run by Ho-Won Lee at 1 site in South Korea.
Trial summary
The purpose of this study is to evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) in improving depressive symptoms in patients with Parkinson's Disease(PD). Participants will be randomly assigned to either an active rTMS group or a sham-control group. Read more about this study
- Who is it for?
- Ages 40 to 90 years
- Conditions the study is for
- Parkinson's Disease, Depression
- What is being tested?
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- 1 siteSouth Korea
- Study dates
- 4 May 2026to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Willing and able to provide written informed consent
- Male or female aged 40 to 90 years
- Diagnosed with Parkinson's disease with depressive symptoms
- Hoehn and Yahr stage 1 to 3
- On stable Parkinson's disease medication for at least 3 months prior to screening, with no planned dose increase during the study period
- Clinically significant depressive symptoms (BDI-II score ≥14) confirmed by clinician interview, without major psychiatric conditions that may confound their assessment
- Able to read and write Korean and capable of independently completing questionnaires
Who cannot join
- History of epilepsy
- Parkinson's disease caused by cerebrovascular disease, CNS infection, intoxication, or traumatic brain injury
- Diagnosed with Parkinson-plus syndromes (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies etc.)
- Clinically significant abnormal laboratory values (AST, ALT, or total bilirubin > 2.5 x ULN)
- Major psychiatric disorders other than depressive disorders (e.g., bipolar disorder, psychotic disorders) that may interfere with study participation or assessment of depressive symptoms
- Unable to follow instructions or communicate
Show all 23Show fewer
- Pregnant, breastfeeding, or women of childbearing potential
- Febrile patients
- Patients with artificial hip joint implants
- Presence of conductive, ferromagnetic, or magnetically sensitive metal near the head or treatment coil (e.g., cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils)
- Cardiac disease, especially patients with pacemakers
- Corrected or uncorrected visual acuity less than 0.5
- Use of drug infusion pumps or hearing aids
- Patients with acute illness
- Patients taking tricyclic antidepressants, neuroleptics, or other medications that may lower seizure threshold
- History of increased intracranial pressure or head trauma
- Evidence of external wounds on brain or neck
- Prominent psychotic symptoms other than depression (high NPI scores for hallucinations, delusions, mania)
- History of schizophrenia, bipolar disorder, or substance abuse
- Suicidal ideation (BDI-II item 9 score of 2 or 3)
- History of or planned deep brain stimulation or stereotactic surgery (pallidotomy, thalamotomy)
- Any participant deemed ineligible by the investigator, including those with medical conditions that may increase risk or interfere with study evaluation
- Currently enrolled in another clinical trial or used investigational drug/device within 30 days or 5 half-lives prior to consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site
Kyungpook National University Chilgok Hospital
Daegu, Buk-gu, 41404
About this study
Official title: Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease : A Single-Center, Randomized, Double-Blinded, Sham-Controlled, Parallel-Design, Investigator-Initiated Exploratory Clinical Trial
The purpose of this study is to evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) in improving depressive symptoms in patients with Parkinson's Disease(PD).
Participants will be randomly assigned to either an active rTMS group or a sham-control group.
The study aims to evaluate the efficacy and feasibility of a neuronavigation-guided bilateral M1 rTMS protocol.
Read the detailed description
Antidepressants and other psychotropic medications must have been stable for 4 weeks before baseline and remain unchanged during the study
At each clinical assessment, the time of the most recent dopaminergic medication dose and the participant's clinical medication state (ON or OFF) will be recorded. Whenever feasible, follow-up assessments will be performed at a similar time relative to the participant's usual dopaminergic medication schedule as at baseline.
- Conditions
- Parkinson's Disease, Depression
- Being tested
- Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Repetitive Transcranial Magnetic Stimulation (Sham rTMS)
- Keywords
- rTMS, Digital Biomarkers, Neuronavigation, Motor Cortex, Neurodegeneration
- Medical subject headings
- Parkinson Disease, Depression, Nerve Degeneration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Repetitive Transcranial Magnetic Stimulation (rTMS)Device
High-frequency rTMS is delivered to bilateral primary motor cortex (M1) using neuronavigation guidance (BrainEyes). Parameters: 10 Hz, 90% of resting motor threshold (RMT), 50 pulses per train, 55-second inter-train interval, 20 trains per session, 1,000 pulses per session, once daily for 5 consecutive weekdays.
Sham Repetitive Transcranial Magnetic Stimulation (Sham rTMS)Device
Sham rTMS is delivered with the coil tilted 90 degrees perpendicular to the scalp to prevent magnetic field delivery to the cortex. The same click sound and scalp sensation are maintained. Session parameters are identical to active rTMS group.
| Study group | Role | What they receive |
|---|---|---|
| Real rTMS | Experimental | Participants receive active repetitive transcranial magnetic stimulation (rTMS) to bilateral primary motor cortex (M1), guided by neuronavigation (BrainEyes). Stimulation is delivered at 10 Hz, 90% of resting motor threshold (RMT), 1,000 pulses per session, once daily for 5 consecutive weekdays. Participants continue their existing Parkinson's disease medication throughout the study. Receives: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) |
| Sham rTMS | Sham comparator | Participants receive sham repetitive transcranial magnetic stimulation (rTMS) to bilateral primary motor cortex (M1), guided by neuronavigation (BrainEyes). The coil is tilted 90 degrees perpendicular to the scalp so that no magnetic field is delivered to the cortex. The same click sound and scalp sensation are maintained to preserve participant blinding. The session parameters are identical to the active rTMS group (10 Hz, 1,000 pulses per session, once daily for 5 consecutive weekdays). Participants continue their existing Parkinson's disease medication throughout the study. Receives: Device: Sham Repetitive Transcranial Magnetic Stimulation (Sham rTMS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Beck Depression Inventory-II (BDI-II) Total Score
The BDI-II is a 21-item self-reported questionnaire assessing the severity of depressive symptoms. Each item is scored from 0 to 3, yielding a total score ranging from 0 to 63, with higher scores indicating greater severity of depressive symptoms. Changes in BDI-II total score from baseline (T0) will be compared between the real rTMS and sham rTMS groups after treatment (T1) and at the follow-up assessment (T2).
Measured: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change From Baseline in Neuropsychiatric Inventory (NPI) Scores
The NPI is a caregiver- or informant-based assessment of neuropsychiatric symptoms. It evaluates 12 neuropsychiatric symptom domains based on symptom frequency and severity. Changes in NPI scores from baseline (T0) will be compared between the real rTMS and sham rTMS groups after treatment (T1) and at the follow-up assessment (T2).
Measured: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Secondary outcomes (14)
Change in Parkinson's Disease Questionnaire-39 (PDQ-39) Scores
Disease-specific questionnaire assessing quality of life in Parkinson's disease patients across 8 domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. Scores range from 0 to 100; higher scores indicate worse quality of life.
Measured: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Scores
Comprehensive clinician-administered scale assessing motor and non-motor symptoms of Parkinson's disease across 6 subscales: non-motor experiences of daily living, motor experiences of daily living, motor examination, motor complications, Hoehn and Yahr staging, and Schwab and England ADL scale. Higher scores indicate greater disease severity.
Measured: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Parkinson's Disease Sleep Scale (PDSS) Scores
Self-reported scale assessing sleep disturbances in Parkinson's disease patients, consisting of 15 items rated on a 5-point Likert scale (0-4). Covers three domains: nocturnal motor symptoms, PD-specific nocturnal symptoms, and sleep-specific disturbances. Higher scores indicate more frequent sleep disturbances.
Measured: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Toronto Alexithymia Scale-20 Korean Version (TAS-20-K) Scores
Korean validated version of the Toronto Alexithymia Scale consisting of 20 items rated on a 5-point Likert scale, assessing three factors: difficulty identifying feelings (DIF), difficulty describing feelings (DDF), and externally oriented thinking (EOT). Higher total scores indicate greater alexithymia.
Measured: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Montreal Cognitive Assessment (MoCA) Scores
Brief cognitive screening tool assessing multiple cognitive domains including attention, concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores range from 0 to 30; higher scores indicate better cognitive function.
Measured: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Facial Expression Measures on FaceReader Analysis
Automated facial expression analysis using FaceReader software to quantitatively assess facial action units (AUs) and emotional expression patterns. Participants perform facial emotion recognition and imitation tasks. Measures include response speed, latency, accuracy, and facial expression accuracy based on Action Unit analysis.
Measured: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Eye Movement Measures on Eye-Tracking
Quantitative assessment of eye movements using screen-based Tobii Pro Spark. Measures include gaze speed, gaze position, gaze duration, gaze latency, and pupil size during task performance, providing objective evaluation of oculomotor function.
Measured: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Muscle Activity Measured by Electromyography (EMG)
Muscle activity is measured using DELSYS Trigno Avanti Sensor and Trigno Quattro Sensor attached to the skin with medical tape. Wireless measurement technology enables free movement during task performance, with real-time data collection via dedicated software.
Measured: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Postural Stability and Balance Measures on BT4 Balance Assessment
Quantitative assessment of postural stability using BT4 balance evaluation system, measuring center of pressure (COP) displacement during standing. Assesses limits of stability in anterior, posterior, and lateral directions, and COP movement during Romberg test under eyes-open and eyes-closed conditions.
Measured: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Body Composition Measured by Bioelectrical Impedance Analysis (InBody)
Basic physical information is collected using InBody580 with 4-pole 8-point tactile electrode method. Bioelectrical impedance is measured across 3 frequency bands (5kHz, 50kHz, 250kHz) in 5 body segments (right arm, left arm, trunk, right leg, left leg), yielding 15 impedance measurements.
Measured: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Electrodermal Activity Measured by Galvanic Skin Response (GSR)
Electrodermal activity is measured using the Shimmer Consensys GSR Development Kit, which records skin conductance changes between electrodes via wireless sensors. Sweat gland activation in response to internal or external stimuli alters skin moisture and ionic balance, producing measurable changes in electrodermal activity.
Measured: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Brain Structure and Connectivity on MRI
Neuroimaging assessment of brain structure using MRI with two sequences: T1-weighted and T2-weighted structural imaging. Used to evaluate structural changes before and after rTMS treatment, and to guide neuronavigation-based TMS targeting.
Measured: Baseline and 1 week (±2 days) after the final stimulation session
Change in Plasma Biomarker Concentrations
Quantitative measurement of candidate plasma biomarkers including Amyloid beta 40/42, Tau, phosphorylated Tau (p-Tau), and Neurofilament light chain (NfL) using antibody-based quantitative analysis methods (SIMOA, Luminex, or ELISA).
Measured: Baseline and immediately after the final stimulation session
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Safety will be assessed by the number and proportion of participants experiencing treatment-emergent adverse events (TEAEs) from the initiation of rTMS or sham stimulation through the final follow-up assessment. Adverse events will be summarized by event type, severity, and relationship to the investigational device. Serious adverse events, adverse device effects, and discontinuations due to adverse events will also be recorded and summarized by treatment group.
Measured: From the first stimulation session to the final stimulation session, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2026
- Study start4 May 2026
- Primary completion27 Nov 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson's DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants are randomly assigned to either real rTMS or sham rTMS group. Both groups continue their existing Parkinson's disease medication throughout the study.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ho-Won Lee
- Sponsor type
- University, hospital or other
- Collaborators
- Korea Brain Research Institute
- Responsible party
- Sponsor-investigator, Ho-Won Lee, Kyungpook National University Chilgok Hospital
- Investigators
- Ho-Won Lee, MD, Principal investigator, Kyungpook National University Chilgok Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07569133
- Sponsor's protocol ID
- KNUCH 2025-08-046-006
- Status last verified
- Oct 2026
- First submitted
- 28 Apr 2026
- Last updated
- 29 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be publicly shared to protect the privacy of the participants. However, de-identified data may be available from the principal investigator upon reasonable request for research purposes, subject to institutional review board approval.
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease : A Single-Center, Randomized, Double-Blinded, Sham-Controlled, Parallel-Design, Investigator-Initiated Exploratory Clinical Trial
- ClinicalTrials.gov ID
- NCT07569133
- Acronym / sponsor ID
- KNUCH 2025-08-046-006
- Conditions
- Parkinson's Disease, Depression
- Keywords
- rTMS, Digital Biomarkers, Neuronavigation, Motor Cortex, Neurodegeneration
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Ho-Won LeeUniversity, hospital or other
- Collaborators
- Korea Brain Research Institute
- Study start
- 4 May 2026 (actual)
- Primary completion
- 27 Nov 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 6 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) in improving depressive symptoms in patients with Parkinson's Disease(PD).
Participants will be randomly assigned to either an active rTMS group or a sham-control group.
The study aims to evaluate the efficacy and feasibility of a neuronavigation-guided bilateral M1 rTMS protocol.
Detailed description
Antidepressants and other psychotropic medications must have been stable for 4 weeks before baseline and remain unchanged during the study
At each clinical assessment, the time of the most recent dopaminergic medication dose and the participant's clinical medication state (ON or OFF) will be recorded. Whenever feasible, follow-up assessments will be performed at a similar time relative to the participant's usual dopaminergic medication schedule as at baseline.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Participants are randomly assigned to either real rTMS or sham rTMS group. Both groups continue their existing Parkinson's disease medication throughout the study.
| Arm | Type | Receives |
|---|---|---|
| Real rTMS | Experimental | Device: Repetitive Transcranial Magnetic Stimulation (rTMS)Participants receive active repetitive transcranial magnetic stimulation (rTMS) to bilateral primary motor cortex (M1), guided by neuronavigation (BrainEyes). Stimulation is delivered at 10 Hz, 90% of resting motor threshold (RMT), 1,000 pulses per session, once daily for 5 consecutive weekdays. Participants continue their existing Parkinson's disease medication throughout the study. |
| Sham rTMS | Sham comparator | Device: Sham Repetitive Transcranial Magnetic Stimulation (Sham rTMS)Participants receive sham repetitive transcranial magnetic stimulation (rTMS) to bilateral primary motor cortex (M1), guided by neuronavigation (BrainEyes). The coil is tilted 90 degrees perpendicular to the scalp so that no magnetic field is delivered to the cortex. The same click sound and scalp sensation are maintained to preserve participant blinding. The session parameters are identical to the active rTMS group (10 Hz, 1,000 pulses per session, once daily for 5 consecutive weekdays). Participants continue their existing Parkinson's disease medication throughout the study. |
Who may qualify
- Ages
- 40 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Willing and able to provide written informed consent
- Male or female aged 40 to 90 years
- Diagnosed with Parkinson's disease with depressive symptoms
- Hoehn and Yahr stage 1 to 3
- On stable Parkinson's disease medication for at least 3 months prior to screening, with no planned dose increase during the study period
Key exclusion criteria (23 listed)
- History of epilepsy
- Parkinson's disease caused by cerebrovascular disease, CNS infection, intoxication, or traumatic brain injury
- Diagnosed with Parkinson-plus syndromes (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies etc.)
- Clinically significant abnormal laboratory values (AST, ALT, or total bilirubin > 2.5 x ULN)
- Major psychiatric disorders other than depressive disorders (e.g., bipolar disorder, psychotic disorders) that may interfere with study participation or assessment of depressive symptoms
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Repetitive Transcranial Magnetic Stimulation (rTMS)High-frequency rTMS is delivered to bilateral primary motor cortex (M1) using neuronavigation guidance (BrainEyes). Parameters: 10 Hz, 90% of resting motor threshold (RMT), 50 pulses per train, 55-second inter-train interval, 20 trains per session, 1,000 pulses per session, once daily for 5 consecutive weekdays. | Device | Real rTMS |
| Sham Repetitive Transcranial Magnetic Stimulation (Sham rTMS)Sham rTMS is delivered with the coil tilted 90 degrees perpendicular to the scalp to prevent magnetic field delivery to the cortex. The same click sound and scalp sensation are maintained. Session parameters are identical to active rTMS group. | Device | Sham rTMS |
Primary outcome
Change From Baseline in Beck Depression Inventory-II (BDI-II) Total Score
Time frame: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
The BDI-II is a 21-item self-reported questionnaire assessing the severity of depressive symptoms. Each item is scored from 0 to 3, yielding a total score ranging from 0 to 63, with higher scores indicating greater severity of depressive symptoms. Changes in BDI-II total score from baseline (T0) will be compared between the real rTMS and sham rTMS groups after treatment (T1) and at the follow-up assessment (T2).
Change From Baseline in Neuropsychiatric Inventory (NPI) Scores
Time frame: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
The NPI is a caregiver- or informant-based assessment of neuropsychiatric symptoms. It evaluates 12 neuropsychiatric symptom domains based on symptom frequency and severity. Changes in NPI scores from baseline (T0) will be compared between the real rTMS and sham rTMS groups after treatment (T1) and at the follow-up assessment (T2).
14 secondary outcomes
Change in Parkinson's Disease Questionnaire-39 (PDQ-39) Scores
Time frame: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Scores
Time frame: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Parkinson's Disease Sleep Scale (PDSS) Scores
Time frame: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Toronto Alexithymia Scale-20 Korean Version (TAS-20-K) Scores
Time frame: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Montreal Cognitive Assessment (MoCA) Scores
Time frame: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Facial Expression Measures on FaceReader Analysis
Time frame: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Eye Movement Measures on Eye-Tracking
Time frame: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Muscle Activity Measured by Electromyography (EMG)
Time frame: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Postural Stability and Balance Measures on BT4 Balance Assessment
Time frame: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Body Composition Measured by Bioelectrical Impedance Analysis (InBody)
Time frame: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Electrodermal Activity Measured by Galvanic Skin Response (GSR)
Time frame: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Brain Structure and Connectivity on MRI
Time frame: Baseline and 1 week (±2 days) after the final stimulation session
Change in Plasma Biomarker Concentrations
Time frame: Baseline and immediately after the final stimulation session
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Time frame: From the first stimulation session to the final stimulation session, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be publicly shared to protect the privacy of the participants. However, de-identified data may be available from the principal investigator upon reasonable request for research purposes, subject to institutional review board approval.
Related trials for Parkinson's Disease
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Not yet recruiting
Compulsive Eating and Brain's Reward System in Different Pathologies
PARKINSON DISEASE (Disorder), Bipolar 1 Disorder
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ho-Won Lee, MD principal investigator
Kyungpook National University Chilgok Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Repetitive Transcranial Magnetic Stimulation (rTMS) in people with Parkinson's Disease and Depression, run by Ho-Won Lee at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Beck Depression Inventory-II (BDI-II) Total Score (time frame: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.